Recursion Pharmaceuticals (RXRX)
(Delayed Data from NSDQ)
$8.59 USD
+0.31 (3.74%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $8.51 -0.08 (-0.93%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RXRX 8.59 +0.31(3.74%)
Will RXRX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for RXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXRX
Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates
RXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know
Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know
Other News for RXRX
Recursion to Participate in Upcoming Investor Conferences
Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX)
Commit To Buy Recursion Pharmaceuticals At $7.50, Earn 32.7% Using Options
How Is The Market Feeling About Recursion Pharmaceuticals?
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool